Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.30 |
| ▸ | PGR | P06401 | 2/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3199165 | 0.85 | TAS1R3 (0.38) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL5126842 | 0.83 | HDAC1 (0.37) | CA12CA2MMP2CA9 | |
| SCHEMBL3202261 | 0.71 | CA14 (0.38) | CA12MMP1MMP2CA9CA14 | |
| SCHEMBL3215829 | 0.71 | RNPEP (0.39) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL5126836 | 0.70 | CA1 (0.35) | CA12CA1CA2CA9LMNA | |
| SCHEMBL11395193 | 0.69 | LMNA (0.35) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL5252419 | 0.68 | NR3C1 (0.32) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL5129198 | 0.67 | CA1 (0.61) | CA12CA1CA2CA9CA14 | |
| SCHEMBL12066041 | 0.66 | CA2 (0.33) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL4233769 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CA12 1162/4885CA1 1123/4885CA2 466/4885 |
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3251/4885CA1 3460/4885CA2 1474/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3135/4885CA1 3746/4885CA2 1306/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | CA12 3251/4885CA1 3460/4885CA2 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.